Bay City Capital backs PharmAkea with Series A

PharmAkea Therapeutics has secured backing from Bay City Capital and Celgene Corporation. Under terms of the agreement, Celgene Corporation will commit $35 million to PharmAkea during an initial three-year alliance term, with an option to extend the collaboration with additional funding. Bay City Capital has invested $10 million in a Series A equity financing.

North AmericaUSBriefs